Major Research Areas

Selected Publications

Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA)in men with moderate PSA-elevation in serum. Int J Cancer. 2005 Sep 8; (Epub ahead of print).

Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther. 2004 Nov;3(11):1439-50.

Vaisanen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem. 2004 Sep;50(9):1607-17

Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate.2003 Feb 15;54(3):181-6.

Return to Prostatic Kallikreins Main Page

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2010 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org